Key Points
- Director Thomas John Dietz sold 20,000 Cypherpunk Technologies shares at an average price of $1.72, reducing his direct ownership by 13.11% to 132,500 shares.
- Cypherpunk shares opened at $1.89, up 16.0%, with a market capitalization of approximately $203.67 million; the company reported quarterly EPS of $0.18.
- Analyst sentiment remains mixed, resulting in an average “Hold” rating and a $1.60 average price target, while institutional investors own 30.46% of the company.
Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) Director Thomas John Dietz sold 20,000 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total transaction of $34,400.00. Following the sale, the director directly owned 132,500 shares in the company, valued at $227,900. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Cypherpunk Technologies Stock Up 16.0%
Shares of NASDAQ:CYPH opened at $1.89 on Friday. The company has a market cap of $203.67 million, a PE ratio of 3.37 and a beta of 0.09. Cypherpunk Technologies has a fifty-two week low of $0.27 and a fifty-two week high of $3.70. The firm has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $0.82.
Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.
Analyst Ratings Changes
CYPH has been the subject of several analyst reports. Wall Street Zen raised shares of Cypherpunk Technologies from a "sell" rating to a "hold" rating in a report on Saturday, July 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $1.60 price objective on shares of Cypherpunk Technologies in a research report on Thursday. Finally, Weiss Ratings upgraded shares of Cypherpunk Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $1.60.
View Our Latest Research Report on Cypherpunk Technologies
Institutional Investors Weigh In On Cypherpunk Technologies
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Simplify Asset Management Inc. acquired a new stake in Cypherpunk Technologies in the fourth quarter worth approximately $2,172,000. Sequoia Financial Advisors LLC acquired a new position in shares of Cypherpunk Technologies during the 4th quarter valued at $56,000. Geode Capital Management LLC acquired a new position in shares of Cypherpunk Technologies during the 4th quarter valued at $615,000. Acadian Asset Management LLC raised its stake in shares of Cypherpunk Technologies by 470.4% in the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company's stock worth $389,000 after buying an additional 1,056,047 shares in the last quarter. Finally, State Street Corp bought a new stake in shares of Cypherpunk Technologies in the 4th quarter worth $163,000. Institutional investors own 30.46% of the company's stock.
About Cypherpunk Technologies
(
Get Free Report)
Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.
DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
